Aberdeen Group Invests $3.25M in Abeona Therapeutics

Biopharmaceutical company receives major funding boost from investment firm

Apr. 9, 2026 at 7:22am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial banking equipment, representing the complex financial infrastructure supporting innovative biopharmaceutical research and development.A major investment from Aberdeen Group signals growing confidence in Abeona Therapeutics' efforts to develop transformative gene and cell therapies.Cleveland Today

Aberdeen Group plc, a prominent investment firm, has acquired a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO), purchasing 616,413 shares valued at approximately $3.25 million. This investment represents 1.14% ownership of the biopharmaceutical company, which focuses on developing gene and cell therapies for rare diseases and oncology indications.

Why it matters

This significant investment from Aberdeen Group underscores the potential of Abeona Therapeutics' pipeline of innovative therapies targeting severe, life-threatening rare diseases. The influx of capital will help the company advance its clinical programs, including gene therapies for neuronal ceroid lipofuscinosis (CLN1 and CLN3) and an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

The details

According to the filing with the Securities and Exchange Commission, Aberdeen Group acquired the 616,413 shares of Abeona Therapeutics in the fourth quarter of the previous year. This investment represents approximately 1.14% of the biopharmaceutical company's outstanding shares.

  • Aberdeen Group acquired the Abeona Therapeutics shares in the fourth quarter of the previous year.

The players

Aberdeen Group plc

A prominent investment firm that has acquired a new position in Abeona Therapeutics Inc., purchasing 616,413 shares valued at approximately $3.25 million.

Abeona Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life-threatening rare diseases and oncology indications.

Got photos? Submit your photos here. ›

The takeaway

This investment from Aberdeen Group is a significant vote of confidence in Abeona Therapeutics' pipeline and its potential to develop groundbreaking therapies for rare and debilitating diseases. The influx of capital will enable the company to accelerate its clinical programs and bring these much-needed treatments one step closer to patients.